TKNO · Alpha Teknova, Inc.
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-05-06 |
Teknova Reports First Quarter 2026 Financial Results
First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year Company reaffirms 2026 revenue guidance of $42-44 million HOLLISTER, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical |
| 2026-04-22 |
Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report |
| 2026-02-26 |
Teknova Reports Fourth Quarter and Full Year 2025 Financial Results
Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidance Fourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior year Company provides 2026 revenue guidance of $42-44 million HOLLISTER, Calif., Feb. |
| 2026-02-05 |
Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report |
| 2025-11-06 |
Teknova Reports Third Quarter 2025 Financial Results
Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. |
| 2025-10-28 |
Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025
HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report |
| 2025-08-07 |
Teknova Reports Second Quarter 2025 Financial Results
Second quarter 2025 total revenue was $10.3 million, up 7% from prior year Achieves four consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. |
| 2025-07-24 |
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report |
| 2025-05-08 |
Teknova Reports First Quarter 2025 Financial Results
First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha |
| 2025-04-24 |
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report |
Past events
Source: https://ir.teknova.com/